Long Ideas - The biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation … Continue Reading
Read NowLong Ideas - Endocyte (NASDAQ:ECYT) recently confirmed that the Marketing Authorization Application (MAA) filing process for vintafolide and etarfolatide in Europe is set to be completed by the end … Continue Reading
Read NowResearch - In November of 2011, Gilead announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO … Continue Reading
Read NowLong Ideas - Shares of Endo Pharmaceuticals (NASDAQ:ENDP) are trading at a deep discount to other pharmaceutical companies, with the last dip in price coming on the heels … Continue Reading
Read NowLong Ideas - One of the most pressing issues that the market faces today is what kind of impact the fiscal cliff will have on companies in the … Continue Reading
Read NowLong Ideas - While investors have been focusing their attention on palifosfamide and the upcoming phase III data, Ziopharm (NASDAQ:ZIOP) released some initial phase I data of Ad-RTS IL-12 … Continue Reading
Read NowLong Ideas - One of the most controversial companies in the biotechnology sector today is Dendreon (NASDAQ:DNDN). To some, the company represents the worst of Wall Street, an … Continue Reading
Read Now